Braveheart Investment Share Discussion Threads

[dave4545] 17/4/2020 14:32

Pharm2Farm
@Pharm2Farm_org
Pharm2Farm has scaled up production of high alcohol sanitiser. Our team are fighting back through innovation! We can win this war with one more sanitiser, face mask and more... #Covid_19 #waragainstcoronavirus #handsanitizer #winning

[dave4545] 17/4/2020 14:31

Pharm2Farm
@Pharm2Farm_org
Pharm2Farm has scaled up production of high alcohol sanitiser. Our team are fighting back through innovation! We can win this war with one more sanitiser, face mask and more... #Covid_19 #waragainstcoronavirus #handsanitizer #winning

[cheshire man] 17/4/2020 10:23

Some of their investments are in vouge atm, think we may be under the radar for now,,,DYOR of course

[dave4545] 17/4/2020 10:00

Welcome.

If you broke down each investment (6) that would be a valuation of 700k each. In stock market terms that is small especially when several have links to c-19

Even the Hand Gel business has great potential to be a big growth company.

Still off the radar.

And has around £1 mil of cash too

[value hound] 17/4/2020 08:50

Indeed. It's bounced, as you would expect, on the COVID-19 stuff, but is only up to last year's NAV (and SP) and that NAV is a very volatile, movable feast given what its investments are - hopefully in a good way. The potential from a mkt cap of just over £4m could be excellent, then again ....

Either way, I suspect it will be a roller-coaster ride over the next few weeks.

[nextlink] 17/4/2020 08:44

This is the 148th post in over eight years.
Given where we are now with the portfolio, we
could be seeing that many posts in days shortly.

[cheshire man] 17/4/2020 08:35

Interesting company dave4545 took a small position yesterday,,,,,,,,

[dave4545] 16/4/2020 21:39

I agree. I've added their twitter accounts in the header.

Unless you have history as a scientist you just have to try and understand the science
or take somebody's else word that it has promise which I do.

The reason I like the Hand Gel side of the business is I have used Gels for years where nobody else touched them. From having a tiny portion in a supermarket and I'm guessing a product that takes a while to sell Hand Gels are going to be massive now.

I estimated from experience that 1-2% of the population used them prior to C-19 and after this I reckon it will jump up to 30-50% a explosion in growth so enough room for plenty of players including pharm2farm

[value hound] 16/4/2020 21:28

Where do you think the real potential lies dave4545? I'm guessing Paraytec and Kirkstall - but it's all Greek to me.

[dave4545] 16/4/2020 20:40

You only have to look at what Nsci did today on their Rns. 5.25p to 19p spike.

If everybody was aware of BRH it would not be below 20p

[value hound] 16/4/2020 18:35

There's certainly a lot of COVID-19 related potential excitement for £4.2m. I wonder what the real NAV could be now?

[dave4545] 16/4/2020 16:16

From twitter and trusted source.

Ivan Spottiswoode
@IvanSpottiswoo1
·
4m
#BRH have big interest in Paraytec who have worked with Aptamer Group and Univ of Sheffield Von using their technology in Bladder Cancer Detection.
You can use this technology in Covid 19 Test Kits and Aptamer are seeking partners.

[dave4545] 16/4/2020 14:58

Could be next one to spike. Little stock out there

[dave4545] 15/4/2020 22:23

@Paraytec1
@EstKirkstall
@Pharm2Farm_org


Braveheart (AIM: BRH), the fund management and strategic investment group, is pleased to provide an operational update on its strategic investments within the context of the COVID-19 pandemic.

Pharm 2 Farm Limited ("P2F") (holding 51.72%)

Pharm2Farm has responded to the COVID-19 pandemic by switching part of its manufacturing facility to the production of medical grade alcohol hand sanitiser gel. Currently manufacturing 500 litres per day, they are supplying NHS fulfilment centres, Regional NHS Clinical Commissioning Groups and other users.

Pharm2Farm has begun testing the efficacy of nano-copper particles' anti-viral properties in Personal Protection Equipment ("PPE"). Nanoparticles are being electrospun into nano fibres that can then be woven into sheets of material. These anti-viral sheets could be laminated into surgical masks and embedded into other PPE to enhance protection. The science team believe that these nano anti-viral fabrics could be further utilised by being applied to filtration systems to help prevent the spread of the airborne virus.

Kirkstall Limited ("Kirkstall") (holding 64.67%)

In response to the COVID-19 pandemic, Kirkstall is targeting specific researchers who are testing drugs on lung cell tissue. Kirkstall has an in vitro cell culture technology, "QuasiVivo", that can be used in the study of respiratory disease which could be faster and more effective than using animals to help understand the disease and the potential efficacy of a vaccine.

COVID-19 is having a major disruptive effect on biomedical research as witnessed by the closure of academic labs worldwide and the forced euthanasia of laboratory animals, some of which had taken years to breed for the specific genotypes the laboratories needed to study immune system responses. The re-starting of laboratory animal experiments will likely take significant time because the pipeline of breeding and nurture has also been disrupted.

Kirkstall believes these conditions will provide an opportunity for a major re-appraisal of whether animal testing methods are appropriate for human relevant research.

Kirkstall has an easy to use QuasiVivo product for in vitro cell culture as a potential replacement for animals and is actively working with leading academics on planning a novel approach to their research once the laboratories re-open.

Phasefocus Holdings Limited ("Phasefocus") (holding 25%)

Following the lifting of the COVID-19 lockdown in China, distributor Sinsi Technology has resumed marketing Phasefocus instruments across the region. It sees a great opportunity to target researchers who will use the LiveCyte instrument to study the effect of viruses on living cells and the performance of drug candidates.

To help support distributors, in this time of restricted travel, the company is releasing a suite of video presentations and webinars to use with customers, explaining the technology and demonstrating capabilities. This work comes on the back of CEO Martin Humphry's successful lecture tour to ten of the leading Canadian research institutions working in cell culture. During this tour he introduced academics to the LiveCyte instrument capabilities and research applications.

Paraytec Limited ("Paraytec") (holding 100%)

In the latest round of the NEXUS project, end user tests with major biopharmaceutical players have been looking at 'virus like particles' (VLPs) that are being used to deliver new gene therapy drugs. Essentially, the active part of a virus is removed and the outer 'shell' is filled with a 'cargo' of the DNA/RNA which constitutes the gene therapy. Biopharma companies need to characterise formulations, to assess critical quality attributes including levels of aggregation and the empty/full ratios of VLPs with nucleic acid cargo. Paraytec's work is early stage but has shown promising results using VLP samples supplied by two biopharmaceutical companies.

Paraytec is moving into the commercial exploitation phase with the outcome of the NEXUS project, the objective being to create a new instrument and look for licensing/commercialisation opportunities. Paraytec is currently having discussions with potential partners who could supply other key elements of the instrument alongside Paraytec's UV imaging system.

Sentinel Medical Limited ("Sentinel") (holding 38.38%)

In addition to the ongoing trials with bladder cancer patient samples, Sentinel is currently awaiting the outcome of a joint grant application with the University of Sheffield, the Aptamer Group and the Leeds Teaching Hospitals NHS Trust for a project to look at aptamers as alternatives to antibodies for bladder cancer detection in urine. Here the aptamers will bind to the cancer cells and Sentinel's technology will be used for reporting the presence of those cells. The science team is currently assessing how this approach could be applied in a COVID-19 point-of-care detection instrument.

[dave4545] 14/4/2020 09:28

N/T at 17p now.

Given all their investments and news today it could get over 20p soon

Super illiquid stock though

[dave4545] 14/4/2020 07:58

boom as they say.

Market cap take out cash is £2.5 mil

Going to be a volatile but good day

[dave4545] 11/4/2020 21:28

Bingo !

Pharm2Farm
@Pharm2Farm_org
·
1h
We are developing a new face mask enabled by our patented nanotechnology as part of the war on COVID-19 #theBMA #WARonCovid19 #facemasks

[dave4545] 09/4/2020 15:32

Been no quote to buy these at 14p for ages now

40k paid 14.5p and the mm's have shook it since but apart from the 10k sold at 12.25 nobody is playing ball and bailing them out like normal

[dave4545] 09/4/2020 13:22

@EstKirkstall

Kirkstall has an in vitro cell culture technology that can be used in the study of respiratory disease and might be faster and more effective than using animals to help understand the disease and the potential efficacy of a vaccine. #TestingForCovid19

[dave4545] 09/4/2020 08:50

smudgedan
@Smudgedann
·
12m
#BRH - over ask paid. One of the only #COVIDー19 shares that hasn't RNS'd yet and has 4 companies involved in the fight

[dave4545] 08/4/2020 21:47

Pharm2Farm
@Pharm2Farm_org
No need to panic Pumba! Pharm2Farm is packed and ready. U can refill with our new 5L pouches..... #handsanitizer #StaySafe #WeGotYou

[dave4545] 08/4/2020 19:17

They also have shares in this company.


@PyreosLtd
· 6h
Today we are announcing priority to shipping #pyroelectric detectors for medical #breathmonitoring systems used with ventilators in response to the high demand due to the Covid-19 coronavirus pandemic:

[dave4545] 08/4/2020 19:17

Yep genuine, looks like the company is setting up twitter accounts for all investments.


@Paraytec1
·
Paraytec is already running a project using our technology to characterise virus like particles for drug delivery. We are now looking to partner with biopharmaceutical companies to help them analyse critical quality attributes of therapeutics and vaccines for viral infections


@EstKirkstall
Animals that were being bred for experimentation are now having to be killed as labs shut down due to COVID - 19. This highlights the importance of working on alternatives to the use of animals in medical research. #COVID19